慢性再生障碍性贫血致重因素中医干预方案的研究

注册号:

Registration number:

ChiCTR-TRC-11001712 

最近更新日期:

Date of Last Refreshed on:

2015-07-23 13:38:02 

注册时间:

Date of Registration:

2011-11-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

慢性再生障碍性贫血致重因素中医干预方案的研究

Public title:

Study on protocol of Traditional Chinese medicine which aim directly at influencing factor in treating chronic aplastic anemia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

慢性再生障碍性贫血致重因素中医干预方案的研究

Scientific title:

Study on protocol of Traditional Chinese medicine which aim directly at influencing factor in treating chronic aplastic anemia

研究课题代号(代码):

Study subject ID:

201107001

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴迪炯 

研究负责人:

周郁鸿 

Applicant:

Wu dijiong 

Study leader:

Zhou yuhong 

申请注册联系人电话:

Applicant telephone:

+86 13989463963

研究负责人电话:

Study leader's
telephone:

+86 13588887286

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wdj850@163.com

研究负责人电子邮件:

Study leader's E-mail:

zyhblood@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

http://www.zjhtcm.com

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市邮电路54号 浙江省中医院血液科

研究负责人通讯地址:

浙江省杭州市邮电路54号 浙江省中医院血液科

Applicant address:

54 Youjian Road, Hangzhou, Zhejiang, China

Study leader's address:

54 Youjian Road, Hangzhou, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

310006

研究负责人邮政编码:

Study leader's postcode:

310006

申请人所在单位:

浙江省中医院血液科

Applicant's institution:

Department of hematology, Traditional Chinese Medical Hospital of Zhejiang Province

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

国中医药科技发[2011]10号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

浙江中医药大学附属第一医院伦理委员会

Name of the ethic committee:

Ethic Committee of First Affiliated Hospital of Zhejiang University of Tradiontal Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2011-07-21 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

国家中医药管理局

Primary sponsor:

State Administration of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

北京市东城区工体西路1号

Primary sponsor's address:

1 West Gongti Road, Dongcheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江省中医院血液科

具体地址:

浙江省杭州市邮电路54号

Institution
hospital:

Department of hematology,Traditional Chinese Medical Hospital of Zhejiang Province

Address:

54 Youjian Road, Hangzhou, Zhejiang, China

经费或物资来源:

2011年中医药行业科研专项

Source(s) of funding:

Project of Tradional Chinese medical industry in 2011

研究疾病:

2011年中医药行业科研专项  

Target disease:

Chronic aplastic anemia

研究疾病代码:

ICD-10:D61.905

Target disease code:

ICD-10:D61.905

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

II期临床试验 

Study phase:

2

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

明确慢性再生障碍性贫血(髓劳病)致重因素及中医药治疗的价值和优势,得出具有循证学依据的研究成果,形成适于基层社区应用的方案体系  

Objectives of Study:

To determine the factor of Chronic aplastic anemia and form the protocol with Tradional Chinese Medicine and to obtained the results which Evidence-Based Medicine may recommend as of high quality. In the future, the protocol should be applyed in community.

药物成份或治疗方案详述:

鹿角胶、仙灵脾、补骨脂、肉苁蓉、菟丝子、巴戟天、仙茅、熟地、 山萸肉、枸杞子、炙黄芪、当归、炒白术、 防风、女贞子、 旱莲草、砂仁 

Description for medicine or protocol of treatment in detail:

Lujiaojiao、xianlingpi,buguzhi,roucongrong,tusizi,bajitian,xianmao,shudi,shanyurou, gouqizi、huangqi,danggui,baishu,fangfeng,nvzhenzi,hanliancao,sharen 

纳入标准:

Inclusion criteria

排除标准:

① 引起全血细胞减少的其他疾病,如阵发性睡眠性血红蛋白尿症、骨髓增生异常综合征、急性造血功能停滞、
骨髓纤维化、急性白血病、恶性组织细胞病等;
② 重型再生障碍性贫血、先天性再生障碍性贫血;
③ 合并严重心、脑、肝、肾疾病及精神病患者;
④ 妊娠、哺乳期妇女;
⑤ 参加其他临床研究。

Exclusion criteria:

1. Other disease which may cause Pancytopenia, such as paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, bone marrow fibrosis, acute leukemia, etc;
2. severe aplastic anemia, congenital aplastic anemia;
3. with severe diseases of heart, brain,liver, kidney, or mental disorder;
4. woman with pregnancy or lactation;
5. take part in other research simultaneously.

研究实施时间:

Study execute time:

From 2011-06-01 00:00:00 To 2013-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2011-10-15 00:00:00 To 2012-10-14 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

225

Group:

treating group

Sample size:

干预措施:

口服中药

干预措施代码:

Intervention:

Traditional Chinese medicine granules

Intervention code:

组别:

B组

样本量:

225

Group:

treating group

Sample size:

干预措施:

雄激素

干预措施代码:

Intervention:

androgen

Intervention code:

组别:

C组

样本量:

225

Group:

control group

Sample size:

干预措施:

安慰剂(1/10治疗中药量+模拟剂)

干预措施代码:

Intervention:

placebo

Intervention code:

组别:

D组

样本量:

225

Group:

control group

Sample size:

干预措施:

雄激素

干预措施代码:

Intervention:

placebo

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江省中医院 

单位级别:

三甲 

Institution
hospital:

Traditional Chinese Medical Hospital of Zhejiang Province

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院西苑医院 

单位级别:

三甲 

Institution
hospital:

xiyuan hospital, China Academy Of Chinese Medical Sciences

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

累计感染发生率

指标类型:

主要指标

Outcome:

Accumulative incidence of infection

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病毒抗体

指标类型:

次要指标

Outcome:

Viral Antibodies

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

Blood routine test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候

指标类型:

次要指标

Outcome:

Signs and symptoms of TCM

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

免疫功能状态

指标类型:

次要指标

Outcome:

Immunal status

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量评分

指标类型:

次要指标

Outcome:

Quality of life

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 14 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

SAS9.1.3统计分析软件产生试验药和对照药编码(编码范围为001-450)

Randomization Procedure (please state who generates the random number sequence and by what method):

SAS9.1.3

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲,对医生和患者实施盲法

Blinding:

Double-blinding for doctor and patients.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

浙江省中医院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Traditional Chinese Medical Hospital of Zhejiang Province

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

中国中医科学院中医临床基础医学研究所

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Institute Of Basic Research In Clinical Medicine, China Academy Of Chinese Medical Sciences

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-07-23 13:38:02